PCSK9 Sponsors May See Opportunity In Off-Label Promotion Court Case
Executive Summary
With robust data on LDL-cholesterol lowering, sponsors of Praluent and Repatha could approach FDA with statements about broader use in lower risk patients, even before cardiovascular outcomes trials complete.